Processa Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Common Share, Disclosure

Net Loss Per Common Share, Disclosure

9 Months Ended

Sep. 30, 2017

6. NET LOSS PER COMMON SHARE:

The Company computes loss per share of common stock using the two-class method required for participating securities. The Companys participating securities include all series of its convertible preferred stock. Undistributed earnings allocated to these participating securities are added to net loss in determining net loss applicable to common stockholders. Basic and Diluted loss per share are computed by dividing net loss applicable to common stockholder by the weighted-average number of shares of common stock outstanding.

Outstanding options and warrants underlying 1,277,123 shares do not assume conversion, exercise or contingent exercise in the computation of diluted loss per share because the effect would be anti-dilutive.

The calculation of the numerator and denominator for basic and diluted net loss per common share is as follows:

	For the three months ended September 30,				For the nine months ended September 30,
	2017		2016		2017		2016
Net loss from continuing operations	$	(204,413)	$	(68,291)	$	(322,891)	$	(246,372)
Net loss from discontinued operations		--		(42)		--		1,214
Net Loss		(204,413)		(68,333)		(322,891)		(245,158)
Basic and diluted:
Preferred stock cumulative dividend - Series D		--		(10,824)		--		(32,234)
Net loss applicable to common stockholders	$	(204,413)	$	(79,157)	$	(322,891)	$	(277,392)
Weighted average shares outstanding used in calculating net loss per common share		11,158,191		11,017,388		11,064,838		11,017,388